141 search results
Pembrolizumab
Keytruda als monotherapie is geïndiceerd als adjuvante behandeling bij volwassenen met stadium III-melanoom waarbij lymfeklieren betrokken zijn en bij wie complete resectie heeft plaatsgevonden.
Pembrolizumab
KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection
Pembrolizumab
First-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations in combination with pemetrexed and platinum chemotherapy.
Pembrolizumab
Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease.
Pembrolizumab
KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum‑based chemotherapy.
Pembrolizumab
Keytruda as monotherapy is indicated for the first‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults.
Pembrolizumab
Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
Pembrolizumab
3L treatment of metastatic castration-resistant prostate cancer (mCRPC), after NHa and chemotherapy treatment (extensively pretreated mCRPC ) combined with Olaparib
Pembrolizumab
Keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a ≥ 50% TPS and progressing on or after platinum-containing chemotherapy. (2L)
Pembrolizumab
1L advanced gastric cancer